Human Stem Cell-Derived Neural Progenitors and Neurons
AMSBIO has introduced a new range of neural progenitor cells, and cerebral cortical neurons, derived from human induced pluripotent stem (iPS) cells.
Despite the large investment and interest in neuroscience traditional methods of studying the human nervous system and disease pathogenesis and mechanisms required the generation of animal models. However, these methods are time consuming, costly and often fail to replicate the desired human pathologies and symptoms.
Using cutting-edge stem cell technologies to generate high purity human neural cells and neurons, AMSBIO is able to provide healthy and Alzheimer disease patient derived cerebral cortical neurons and neural progenitor cells. This accessible, in vitro human-based system offers a platform to build human cellular models to study conditions including Alzheimer’s, autism, epilepsy, traumatic brain injury and stroke. Derived using integration-free fully defined neural induction conditions, these cells are electrically active, form functional synapses in vitro and can be transplanted into animal models.
Available in industrial quantities, AMSBIO cerebral cortical neurons and neural progenitor cells are supplied with extensive functional and molecular characterization data. All products are supplied ready-made and remain viable in culture for months to facilitate reproducible and long-term studies. Cells from multiple donors are available for purchase allowing data comparison among biological replicates.
Alzheimer’s disease is the most common neurodegenerative disorder, now affecting more than 24 million people worldwide. Predicted to reach 100 million by 2050, this technology platform has been focused on providing both healthy and Alzheimer’s disease relevant human neurons derived from iPS cells to complement existing studies of this condition.
Related News
-
News Women in Pharma: Moving beyond discussions and into best practice at CPHI Milan
In this second CPHI Milan special of our monthly series, we cover the key takeaways from the Diversity & Wellbeing track held on October 10, 2024. -
News AstraZeneca invests in AI collaboration for cancer drug trials
The British-Swedish pharmaceutical giant is partnering with biotechnology firm Immunai Inc to increase the efficiency of some cancer drug trials. -
News Ozempic and Wegovy prices questioned as Novo Nordisk faces US Senate hearing
The CEO of Novo Nordisk was grilled during a US Senate committee hearing on September 24, 2024, in which the exorbitant prices of the Danish company’s blockbuster drugs Ozempic and Wegovy were called into question. -
News The BIOSECURE Act: implications for the pharma supply chain
On September 9, 2024, the US House of Representatives voted to pass the bill titled the BIOSECURE Act (the Act), which lists several Chinese companies in the pharmaceutical supply chain. The Act will prohibit American companies from contracting or doin... -
News On Track at CPHI Milan: Thermo Fisher Scientific Track Sponsor interview
With CPHI Milan just around the corner, we sat down with some of the sponsors for this year’s conference tracks to discuss the most pressing topics in pharma. -
News CPHI Milan Speaker Spotlight: Pharma Manufacturing and Localisation in Africa
In the run-up to CPHI Milan, we sit down with some of the experts and thought-leaders speaking at this year’s conferences. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Eli Lilly licenses rheumatoid arthritis manufacturing in Africa
American pharmaceutical company Eli Lilly has signed a partnership with Egyptian organisation Eva Pharma to localise manufacturing of rheumatoid arthritis treatments in Africa.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance